Novel combination strategy to optimize treatment for PTSD

Mujeeb Shad, Alina M. Suris, Carol S. North

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Post-traumatic stress disorder (PTSD) is increasingly recognized as a serious and potentially debilitating condition in combat veterans returning from Iraq and Afghanistan. Exposure to a potentially life-threatening event such as military combat may be followed by PTSD. Despite recent advances in pharmacotherapy for PTSD, monotherapy with the currently available medications is only partially effective, as demonstrated in large clinical trials of combat veterans with PTSD. This underscores the need to investigate novel combination strategies to enhance treatment response in PTSD. The α-1 adrenergic receptor (AR) antagonist, prazosin, appears promising in recent studies for its capacity to reduce trauma-related nightmares (a group B night-time intrusion symptom) and insomnia (a group D night-time arousal symptom), while recent evidence supports using the β-AR antagonist, propranolol, to dampen the emotional content of traumatic memories (daytime intrusion symptoms including flashbacks, intrusive recollections of traumatic event, and heightened physiological reactivity/responsivity to trauma reminders). In this review, we present data supporting the potential utility of combined drug regimen (prazosin and propranolol) acting through different noradrenergic mechanisms, with the potential to target more than one set of PTSD symptoms to optimize PTSD treatment.

Original languageEnglish (US)
Pages (from-to)4-11
Number of pages8
JournalHuman Psychopharmacology
Volume26
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Post-Traumatic Stress Disorders
Adrenergic Antagonists
Prazosin
Veterans
Propranolol
Therapeutics
Afghanistan
Iraq
Wounds and Injuries
Sleep Initiation and Maintenance Disorders
Arousal
Clinical Trials
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Combination
  • Novel
  • PTSD
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)

Cite this

Novel combination strategy to optimize treatment for PTSD. / Shad, Mujeeb; Suris, Alina M.; North, Carol S.

In: Human Psychopharmacology, Vol. 26, No. 1, 01.2011, p. 4-11.

Research output: Contribution to journalArticle

Shad, Mujeeb ; Suris, Alina M. ; North, Carol S. / Novel combination strategy to optimize treatment for PTSD. In: Human Psychopharmacology. 2011 ; Vol. 26, No. 1. pp. 4-11.
@article{4088c30dd9974cc8a254c759a73424f4,
title = "Novel combination strategy to optimize treatment for PTSD",
abstract = "Post-traumatic stress disorder (PTSD) is increasingly recognized as a serious and potentially debilitating condition in combat veterans returning from Iraq and Afghanistan. Exposure to a potentially life-threatening event such as military combat may be followed by PTSD. Despite recent advances in pharmacotherapy for PTSD, monotherapy with the currently available medications is only partially effective, as demonstrated in large clinical trials of combat veterans with PTSD. This underscores the need to investigate novel combination strategies to enhance treatment response in PTSD. The α-1 adrenergic receptor (AR) antagonist, prazosin, appears promising in recent studies for its capacity to reduce trauma-related nightmares (a group B night-time intrusion symptom) and insomnia (a group D night-time arousal symptom), while recent evidence supports using the β-AR antagonist, propranolol, to dampen the emotional content of traumatic memories (daytime intrusion symptoms including flashbacks, intrusive recollections of traumatic event, and heightened physiological reactivity/responsivity to trauma reminders). In this review, we present data supporting the potential utility of combined drug regimen (prazosin and propranolol) acting through different noradrenergic mechanisms, with the potential to target more than one set of PTSD symptoms to optimize PTSD treatment.",
keywords = "Combination, Novel, PTSD, Treatment",
author = "Mujeeb Shad and Suris, {Alina M.} and North, {Carol S.}",
year = "2011",
month = "1",
doi = "10.1002/hup.1171",
language = "English (US)",
volume = "26",
pages = "4--11",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Novel combination strategy to optimize treatment for PTSD

AU - Shad, Mujeeb

AU - Suris, Alina M.

AU - North, Carol S.

PY - 2011/1

Y1 - 2011/1

N2 - Post-traumatic stress disorder (PTSD) is increasingly recognized as a serious and potentially debilitating condition in combat veterans returning from Iraq and Afghanistan. Exposure to a potentially life-threatening event such as military combat may be followed by PTSD. Despite recent advances in pharmacotherapy for PTSD, monotherapy with the currently available medications is only partially effective, as demonstrated in large clinical trials of combat veterans with PTSD. This underscores the need to investigate novel combination strategies to enhance treatment response in PTSD. The α-1 adrenergic receptor (AR) antagonist, prazosin, appears promising in recent studies for its capacity to reduce trauma-related nightmares (a group B night-time intrusion symptom) and insomnia (a group D night-time arousal symptom), while recent evidence supports using the β-AR antagonist, propranolol, to dampen the emotional content of traumatic memories (daytime intrusion symptoms including flashbacks, intrusive recollections of traumatic event, and heightened physiological reactivity/responsivity to trauma reminders). In this review, we present data supporting the potential utility of combined drug regimen (prazosin and propranolol) acting through different noradrenergic mechanisms, with the potential to target more than one set of PTSD symptoms to optimize PTSD treatment.

AB - Post-traumatic stress disorder (PTSD) is increasingly recognized as a serious and potentially debilitating condition in combat veterans returning from Iraq and Afghanistan. Exposure to a potentially life-threatening event such as military combat may be followed by PTSD. Despite recent advances in pharmacotherapy for PTSD, monotherapy with the currently available medications is only partially effective, as demonstrated in large clinical trials of combat veterans with PTSD. This underscores the need to investigate novel combination strategies to enhance treatment response in PTSD. The α-1 adrenergic receptor (AR) antagonist, prazosin, appears promising in recent studies for its capacity to reduce trauma-related nightmares (a group B night-time intrusion symptom) and insomnia (a group D night-time arousal symptom), while recent evidence supports using the β-AR antagonist, propranolol, to dampen the emotional content of traumatic memories (daytime intrusion symptoms including flashbacks, intrusive recollections of traumatic event, and heightened physiological reactivity/responsivity to trauma reminders). In this review, we present data supporting the potential utility of combined drug regimen (prazosin and propranolol) acting through different noradrenergic mechanisms, with the potential to target more than one set of PTSD symptoms to optimize PTSD treatment.

KW - Combination

KW - Novel

KW - PTSD

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79953239432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953239432&partnerID=8YFLogxK

U2 - 10.1002/hup.1171

DO - 10.1002/hup.1171

M3 - Article

VL - 26

SP - 4

EP - 11

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -